Effect of repaglinide on cloned beta cell, cardiac and smooth muscle types of ATP-sensitive potassium channels.

AIMS/HYPOTHESIS: The carbamoylbenzoic acid derivative repaglinide is a potent short-acting insulin secretagogue that acts by closing ATP-sensitive potassium (KATP) channels in the plasma membrane of the pancreatic beta cell. In this paper we investigated. the specificity of repaglinide for three typ...

Full description

Bibliographic Details
Main Authors: Dabrowski, M, Wahl, P, Holmes, W, Ashcroft, F
Format: Journal article
Language:English
Published: 2001
_version_ 1797068795138801664
author Dabrowski, M
Wahl, P
Holmes, W
Ashcroft, F
author_facet Dabrowski, M
Wahl, P
Holmes, W
Ashcroft, F
author_sort Dabrowski, M
collection OXFORD
description AIMS/HYPOTHESIS: The carbamoylbenzoic acid derivative repaglinide is a potent short-acting insulin secretagogue that acts by closing ATP-sensitive potassium (KATP) channels in the plasma membrane of the pancreatic beta cell. In this paper we investigated. the specificity of repaglinide for three types of cloned (KATP) channel composed of the inwardly rectifying potassium channel Kir6.2 and either the sulphonylurea receptor SUR1, SUR2A or SUR2B, corresponding to the beta cell, cardiac and either smooth muscle types of KATP channel, respectively. METHODS: The action of the drug was studied by whole-cell current recordings of KATP channels expressed either in Xenopus oocytes or mammalian cells (HEK293). We also used inside-out macropatches excised from Xenopus oocytes for detailed analysis of repaglinide action. RESULTS: The drug blocked all three types of KATP channel with similar potency, by interacting with a low-affinity site on the pore-forming subunit of the channel (Kir6.2: half-maximal inhibition 230 micromol/l) and with a high-affinity site on the regulatory subunit, the sulphonylurea receptor (SUR: half-maximal inhibition 2-8 nmol/l). There was no difference in potency between channels containing SUR1, SUR2A or SUR2B. MgADP potentiated the inhibitory effect of repaglinide on Kir6.2/SUR1 and (to a lesser extent) Kir6.2/SUR2B, but not on Kir6.2/SUR2A. CONCLUSION/INTERPRETATION: Repaglinide interacts with a site common to all three types of sulphonylurea receptor leading to inhibition of the KATP channel. The fact that MgADP potentiated this effect in the case of the beta cell, but not cardiac, type of channel could help explain why the drug shows no adverse cardiovascular side-effects in vivo.
first_indexed 2024-03-06T22:15:15Z
format Journal article
id oxford-uuid:532b86e4-22e8-4466-9365-69d6f5569dea
institution University of Oxford
language English
last_indexed 2024-03-06T22:15:15Z
publishDate 2001
record_format dspace
spelling oxford-uuid:532b86e4-22e8-4466-9365-69d6f5569dea2022-03-26T16:30:01ZEffect of repaglinide on cloned beta cell, cardiac and smooth muscle types of ATP-sensitive potassium channels.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:532b86e4-22e8-4466-9365-69d6f5569deaEnglishSymplectic Elements at Oxford2001Dabrowski, MWahl, PHolmes, WAshcroft, FAIMS/HYPOTHESIS: The carbamoylbenzoic acid derivative repaglinide is a potent short-acting insulin secretagogue that acts by closing ATP-sensitive potassium (KATP) channels in the plasma membrane of the pancreatic beta cell. In this paper we investigated. the specificity of repaglinide for three types of cloned (KATP) channel composed of the inwardly rectifying potassium channel Kir6.2 and either the sulphonylurea receptor SUR1, SUR2A or SUR2B, corresponding to the beta cell, cardiac and either smooth muscle types of KATP channel, respectively. METHODS: The action of the drug was studied by whole-cell current recordings of KATP channels expressed either in Xenopus oocytes or mammalian cells (HEK293). We also used inside-out macropatches excised from Xenopus oocytes for detailed analysis of repaglinide action. RESULTS: The drug blocked all three types of KATP channel with similar potency, by interacting with a low-affinity site on the pore-forming subunit of the channel (Kir6.2: half-maximal inhibition 230 micromol/l) and with a high-affinity site on the regulatory subunit, the sulphonylurea receptor (SUR: half-maximal inhibition 2-8 nmol/l). There was no difference in potency between channels containing SUR1, SUR2A or SUR2B. MgADP potentiated the inhibitory effect of repaglinide on Kir6.2/SUR1 and (to a lesser extent) Kir6.2/SUR2B, but not on Kir6.2/SUR2A. CONCLUSION/INTERPRETATION: Repaglinide interacts with a site common to all three types of sulphonylurea receptor leading to inhibition of the KATP channel. The fact that MgADP potentiated this effect in the case of the beta cell, but not cardiac, type of channel could help explain why the drug shows no adverse cardiovascular side-effects in vivo.
spellingShingle Dabrowski, M
Wahl, P
Holmes, W
Ashcroft, F
Effect of repaglinide on cloned beta cell, cardiac and smooth muscle types of ATP-sensitive potassium channels.
title Effect of repaglinide on cloned beta cell, cardiac and smooth muscle types of ATP-sensitive potassium channels.
title_full Effect of repaglinide on cloned beta cell, cardiac and smooth muscle types of ATP-sensitive potassium channels.
title_fullStr Effect of repaglinide on cloned beta cell, cardiac and smooth muscle types of ATP-sensitive potassium channels.
title_full_unstemmed Effect of repaglinide on cloned beta cell, cardiac and smooth muscle types of ATP-sensitive potassium channels.
title_short Effect of repaglinide on cloned beta cell, cardiac and smooth muscle types of ATP-sensitive potassium channels.
title_sort effect of repaglinide on cloned beta cell cardiac and smooth muscle types of atp sensitive potassium channels
work_keys_str_mv AT dabrowskim effectofrepaglinideonclonedbetacellcardiacandsmoothmuscletypesofatpsensitivepotassiumchannels
AT wahlp effectofrepaglinideonclonedbetacellcardiacandsmoothmuscletypesofatpsensitivepotassiumchannels
AT holmesw effectofrepaglinideonclonedbetacellcardiacandsmoothmuscletypesofatpsensitivepotassiumchannels
AT ashcroftf effectofrepaglinideonclonedbetacellcardiacandsmoothmuscletypesofatpsensitivepotassiumchannels